Arbutus announces conclusion of LNP license agreement with Alexion
Arbutus Biopharma announced it has received notice of termination from Alexion Pharmaceuticals for the companies' LNP license agreement, which was signed and announced in March 2017. Alexion's termination of the LNP license agreement was driven by a strategic review of Alexion's business portfolio. July 27, 2017